IDEXX LABORATORIES INC /DE — Director's Dealing 2020

Jun 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2020-05-29

Reporting Person: TWIGGE GIOVANI (CORPORATE VICE PRESIDENT)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-29	Common Stock	M	12814	$62	Acquired	25706	Direct
2020-05-29	Common Stock	M	1256	$79.54	Acquired	26962	Direct
2020-05-29	Common Stock	S	359	$304.7627	Disposed	26603	Direct
2020-05-29	Common Stock	S	1600	$306.2094	Disposed	25003	Direct
2020-05-29	Common Stock	S	3948	$306.9851	Disposed	21005	Direct
2020-05-29	Common Stock	S	3296	$307.9895	Disposed	17759	Direct
2020-05-29	Common Stock	S	4867	$308.8759	Disposed	12892	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-29	Non-Qualified Stock Option (right-to-buy)	$62	M	12814	Disposed	2024-02-13	Common Stock (12814)	Direct
2020-05-29	Incentive Stock Option (right-to-buy)	$79.54	M	1256	Disposed	2025-02-13	Common Stock (1256)	Direct

Footnotes

F1: Includes 23 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2020.

F2: Represents the weighted average price of the shares sold ranging from a low of $304.46 to a high of $304.98 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F3: Represents the weighted average price of the shares sold ranging from a low of $305.55 to a high of $306.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F4: Represents the weighted average price of the shares sold ranging from a low of $306.58 to a high of $307.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F5: Represents the weighted average price of the shares sold ranging from a low of $307.60 to a high of $308.41 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F6: Represents the weighted average price of the shares sold ranging from a low of $308.62 to a high of $309.40 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F7: Grant of option to buy 6,407 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F8: Grant of option to buy 628 shares of IDEXX Laboratories, Inc. common stock that became exercisable on February 14, 2020 without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F9: Not applicable.